TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.41B
EPS5.6000
P/E Ratio12.44
Earnings Date07/29/2026

tmdx

Selling, General and Administrative Expenses

Last Annual Value

185.17M

3-Year CAGR

38%

5-Year CAGR

50%

10-Year CAGR

37%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of Selling, General and Administrative Expenses

TMDX · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
185.17M
15.7%37.1%36.7% 
37.93M
6.9%14.7%N/A
329.33M
13.7%12.9%17.7%
946.50M
9.1%11.0%9.3%
646.46M
44.4%N/AN/A
68.20M
7.4%13.4%N/A
634.00M
3.7%8.0%4.4%
106.30M
41.4%79.7%N/A
2.05B
N/A50.5%N/A
682.45M
4.0%5.4%33.2%
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
76.24M
16.7%14.0%N/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $69.69, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $69.69